Bidirectional Modulation of the Tumor Immune Microenvironment by Gut Microbiota‐Derived Indoles: Mechanisms and Therapeutic Potential
The FASEB Journal · 31.07.2026 · 40 (14)
DOI: 10.1096/fj.202601162r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 24.07.2026. Verfasst von Chaowei Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College of Guizhou University of Traditional Chinese Medicine, Guizhou, China. Hauptthemen laut MEDLINE: Indoles, Tumor Microenvironment, Gastrointestinal Microbiome, Neoplasms. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The National Natural Science Foundation of China, Special Funds for High-level Creative Talents Cultivation in Guizhou Province, Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Trans-formation.
Abstract (Originalsprache)
The tumor immune microenvironment (TIME) plays a decisive role in cancer progression and therapeutic response. Emerging evidence highlights gut microbiota‐derived indole metabolites, produced from dietary tryptophan, as key regulators of tumor immunity. These metabolites function through complex metabolic networks and exert dual immunomodulatory effects: they can enhance antitumor immunity by promoting CD8 + T cell stemness, increasing tumor immunogenicity, and relieving immunosuppression, while also suppressing immunity by inducing regulatory T cells (Tregs), M2 macrophage polarization, and anti‐inflammatory cytokine production. This review systematically summarizes the biosynthetic pathways and microbial sources of major indole compounds, and discusses their context‐dependent roles in shaping the TIME via aryl hydrocarbon receptor (AhR)–dependent and –independent mechanisms. Unlike previous reviews that often extrapolate findings from non‐tumor inflammation models to cancer without adequate contextualization, we critically evaluate evidence from both tumor and non‐tumor models, with explicit distinction between direct tumor‐relevant findings and speculative insights for the tumor immune microenvironment (TIME). Special attention is given to the therapeutic potential of indoles as adjuvants to immune checkpoint blockade and their promise in precision immuno‐oncology. By integrating microbiology, immunology, and metabolomics, we aim to provide a theoretical foundation for developing indole‐based strategies to overcome immunotherapy resistance and improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
- Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Chinese Medicine Guangdong Laboratory, Guangdong, China.
ORCID-Profile: Chaowei Wang
Förderung
- The National Natural Science Foundation of China
- Special Funds for High-level Creative Talents Cultivation in Guizhou Province
- Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Trans-formation
- Open Foundation of Chinese Medicine Guangdong Laboratory
Zitieren
APA
Wang, C., Bi, L., & Wang, Y. (2026). Bidirectional Modulation of the Tumor Immune Microenvironment by Gut Microbiota‐Derived Indoles: Mechanisms and Therapeutic Potential. The FASEB Journal, 40(14). https://doi.org/10.1096/fj.202601162r
Vancouver
Wang C, Bi L, Wang Y. Bidirectional Modulation of the Tumor Immune Microenvironment by Gut Microbiota‐Derived Indoles: Mechanisms and Therapeutic Potential. The FASEB Journal. 2026;40(14). doi:10.1096/fj.202601162r
BibTeX
@article{Wang2026,
author = {Wang, Chaowei and Bi, Ling and Wang, Yan},
title = {Bidirectional Modulation of the Tumor Immune Microenvironment by Gut Microbiota‐Derived Indoles: Mechanisms and Therapeutic Potential},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {14},
doi = {10.1096/fj.202601162r}
}
EUVIMED